Aragen Life Sciences (formerly GVK BIO), a contract research and development organisation, headquartered out of Hyderabad, India, announces an expansion of their discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.

This partnership allows Boehringer Ingelheim to incorporate several design elements, synthesise, profile, and then characterise a wide range of chemotypes against key targets of interest in swift optimisation cycles. The partnership also allows for the integrated up-scaling of compounds for larger pre-clinical studies. Biology screening of appropriate chemical moieties to drive decision making with speed and accuracy is also included in the partnership. Aragen will dedicate a sizeable portion of its campus in Hyderabad to support this alliance.

“We at Aragen believe that ‘In Every Molecule is the Possibility for Better Health’, and are excited about the opportunity to expand our partnership with Boehringer Ingelheim, a global leader in the discovery and development of novel medicines. It has been our privilege to collaborate with the scientists at Boehringer Ingelheim, and we thank them for their trust and confidence in the Aragen team. Together, we look forward to advancing Boehringer Ingelheim’s innovative approaches into successful clinical outcomes that can have the potential to ultimately benefit patients,” said Manni Kantipudi, CEO at Aragen.